Engineered Extracellular Vesicles for Ischemic Stroke: a Systematic Review and Meta-analysis of Preclinical Studies

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2023 Oct 31

PMID 37904204

Authors

Pengtao Li

Rui Yin

Yihao Chen

Jianbo Chang

Lang Yang

Xiaoyu Liu

Houshi Xu

Xiao Zhang

Shihua Wang

Qin Han

Junji Wei

Affiliations

Soon will be listed here.

Abstract

Background: This systematic review and meta-analysis aimed to evaluate the efficacy of engineered extracellular vesicles (EEVs) in the treatment of ischemic stroke (IS) in preclinical studies and to compare them with natural extracellular vesicles (EVs). The systematic review provides an up-to-date overview of the current state of the literature on the use of EEVs for IS and informs future research in this area.

Methods: We searched PubMed, EMBASE, Web of Science, Cochrane Library, and Scopus databases for peer-reviewed preclinical studies on the therapeutic effect of EEVs on IS.Databases ranged from the inception to August 1, 2023. The outcome measures included infarct volumes, neurological scores, behavioral scores, apoptosis rates, numbers of neurons, and levels of IL-1β, IL-6, and TNF-α. The CAMARADES checklist was used to assess the quality and bias risks of the studies. All statistical analyses were performed using RevMan 5.4 software.

Results: A total of 28 studies involving 1760 animals met the inclusion criteria. The results of the meta-analysis showed that compared to natural EVs, EEVs reduced infarct volume (percentage: SMD = -2.33, 95% CI: -2.92, -1.73; size: SMD = -2.36, 95% CI: -4.09, -0.63), improved neurological scores (mNSS: SMD = -1.78, 95% CI: -2.39, -1.17; Zea Longa: SMD = -2.75, 95% CI: -3.79, -1.71), promoted behavioral recovery (rotarod test: SMD = 2.50, 95% CI: 1.81, 3.18; grid-walking test: SMD = -3.45, 95% CI: -5.15, -1.75; adhesive removal test: SMD = -2.60, 95% CI: -4.27, -0.93; morris water maze test: SMD = -3.91, 95% CI: -7.03, -0.79), and reduced the release of proinflammatory factors (IL-1β: SMD = -2.02, 95% CI: -2.77, -1.27; IL-6: SMD = -3.01, 95% CI: -4.47, -1.55; TNF-α: SMD = -2.72, 95% CI: -4.30, -1.13), increasing the number of neurons (apoptosis rate: SMD = -2.24, 95% CI: -3.32, -1.16; the number of neurons: SMD = 3.70, 95% CI: 2.44, 4.96). The funnel plots for the two main outcome measures were asymmetric, indicating publication bias. The median score on the CAMARADES checklist was 7 points (IQR: 6-9).

Conclusions: This meta-analysis shows that EEVs are superior to natural EVs for the treatment of IS. However, research in this field is still at an early stage, and more research is needed to fully understand the potential therapeutic mechanism of EEVs and their potential use in the treatment of IS.

Prospero Registration Number: CRD42022368744.

Citing Articles

Stem Cell-Derived Extracellular Vesicles for Acute Pancreatitis: a Systematic Review and Meta-analysis of Preclinical Studies.

Hong Y, Ye M, Wang J, Huang L Stem Cell Rev Rep. 2025; .

PMID: 39964640 DOI: 10.1007/s12015-025-10852-5.

Emerging roles of mechanosensitive ion channels in ventilator induced lung injury: a systematic review.

Liu G, Dong B, Devanarayana S, Chen R, Liu Q Front Immunol. 2024; 15:1479230.

PMID: 39664395 PMC: 11631737. DOI: 10.3389/fimmu.2024.1479230.

Engineered extracellular vesicles for tissue repair and regeneration.

Zhang Y, Wu D, Zhou C, Bai M, Wan Y, Zheng Q Burns Trauma. 2024; 12:tkae062.

PMID: 39439545 PMC: 11495891. DOI: 10.1093/burnst/tkae062.

A meta-analysis of animal studies evaluating the effect of hydrogen sulfide on ischemic stroke: is the preclinical evidence sufficient to move forward?.

Emre Aydingoz S, Teimoori A, Orhan H, Demirtas E, Zeynalova N Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9533-9548.

PMID: 39017715 PMC: 11582254. DOI: 10.1007/s00210-024-03291-5.

Revolutionizing Ischemic Stroke Diagnosis and Treatment: The Promising Role of Neurovascular Unit-Derived Extracellular Vesicles.

Gao X, Liu D, Yue K, Zhang Z, Jiang X, Luo P Biomolecules. 2024; 14(3).

PMID: 38540796 PMC: 10967973. DOI: 10.3390/biom14030378.

References

Budnik V, Ruiz-Canada C, Wendler F . Extracellular vesicles round off communication in the nervous system. Nat Rev Neurosci. 2016; 17(3):160-72. PMC: 4989863. DOI: 10.1038/nrn.2015.29. View

Xu X, Zhang H, Li J, Chen Y, Zhong W, Chen Y . Combination of EPC-EXs and NPC-EXs with miR-126 and miR-210 overexpression produces better therapeutic effects on ischemic stroke by protecting neurons through the Nox2/ROS and BDNF/TrkB pathways. Exp Neurol. 2022; 359:114235. DOI: 10.1016/j.expneurol.2022.114235. View

Zhao Y, Gan Y, Xu G, Hua K, Liu D . Exosomes from MSCs overexpressing microRNA-223-3p attenuate cerebral ischemia through inhibiting microglial M1 polarization mediated inflammation. Life Sci. 2020; 260:118403. DOI: 10.1016/j.lfs.2020.118403. View

Kim H, Kim T, Kang L, Kim Y, Kang M, Kim J . Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke. Biomaterials. 2020; 243:119942. DOI: 10.1016/j.biomaterials.2020.119942. View

Yang H, Zhang M, Wu R, Zheng H, Zhang L, Luo J . C-C chemokine receptor type 2-overexpressing exosomes alleviated experimental post-stroke cognitive impairment by enhancing microglia/macrophage M2 polarization. World J Stem Cells. 2020; 12(2):152-167. PMC: 7062036. DOI: 10.4252/wjsc.v12.i2.152. View

Guo L, Huang Z, Huang L, Liang J, Wang P, Zhao L . Surface-modified engineered exosomes attenuated cerebral ischemia/reperfusion injury by targeting the delivery of quercetin towards impaired neurons. J Nanobiotechnology. 2021; 19(1):141. PMC: 8130330. DOI: 10.1186/s12951-021-00879-4. View

Zhou H, Zhou J, Teng H, Yang H, Qiu J, Li X . MiR-145 enriched exosomes derived from bone marrow-derived mesenchymal stem cells protects against cerebral ischemia-reperfusion injury through downregulation of FOXO1. Biochem Biophys Res Commun. 2022; 632:92-99. DOI: 10.1016/j.bbrc.2022.09.089. View

Li F, Zhao L, Shi Y, Liang J . Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. Mol Pharm. 2020; 17(9):3192-3201. DOI: 10.1021/acs.molpharmaceut.0c00245. View

Tian T, Cao L, He C, Ye Q, Liang R, You W . Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia. Theranostics. 2021; 11(13):6507-6521. PMC: 8120222. DOI: 10.7150/thno.56367. View

10.

Cun Y, Jin Y, Wu D, Zhou L, Zhang C, Zhang S . Exosome in Crosstalk between Inflammation and Angiogenesis: A Potential Therapeutic Strategy for Stroke. Mediators Inflamm. 2022; 2022:7006281. PMC: 9427301. DOI: 10.1155/2022/7006281. View

11.

Toh W, Zhang B, Lai R, Lim S . Immune regulatory targets of mesenchymal stromal cell exosomes/small extracellular vesicles in tissue regeneration. Cytotherapy. 2018; 20(12):1419-1426. DOI: 10.1016/j.jcyt.2018.09.008. View

12.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

13.

Zhu Z, Jia F, Ahmed W, Zhang G, Wang H, Lin C . Neural stem cell-derived exosome as a nano-sized carrier for BDNF delivery to a rat model of ischemic stroke. Neural Regen Res. 2022; 18(2):404-409. PMC: 9396474. DOI: 10.4103/1673-5374.346466. View

14.

Yang C, Yuan F, Shao W, Yao L, Jin S, Han F . Protective role of exosomes derived from regulatory T cells against inflammation and apoptosis of BV-2 microglia under oxygen-glucose deprivation/reperfusion challenge. Genet Mol Biol. 2022; 45(4):e20220119. PMC: 9764325. DOI: 10.1590/1678-4685-GMB-2022-0119. View

15.

Zi W, Qiu Z, Li F, Sang H, Wu D, Luo W . Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. JAMA. 2021; 325(3):234-243. PMC: 7816099. DOI: 10.1001/jama.2020.23523. View

16.

Pan Q, Kuang X, Cai S, Wang X, Du D, Wang J . miR-132-3p priming enhances the effects of mesenchymal stromal cell-derived exosomes on ameliorating brain ischemic injury. Stem Cell Res Ther. 2020; 11(1):260. PMC: 7322840. DOI: 10.1186/s13287-020-01761-0. View

17.

Kim M, Kim G, Hwang D, Lee M . Delivery of High Mobility Group Box-1 siRNA Using Brain-Targeting Exosomes for Ischemic Stroke Therapy. J Biomed Nanotechnol. 2019; 15(12):2401-2412. DOI: 10.1166/jbn.2019.2866. View

18.

Macleod M, OCollins T, Howells D, Donnan G . Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004; 35(5):1203-8. DOI: 10.1161/01.STR.0000125719.25853.20. View

19.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood M . Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4):341-5. DOI: 10.1038/nbt.1807. View

20.

Xin H, Katakowski M, Wang F, Qian J, Liu X, Ali M . MicroRNA cluster miR-17-92 Cluster in Exosomes Enhance Neuroplasticity and Functional Recovery After Stroke in Rats. Stroke. 2017; 48(3):747-753. PMC: 5330787. DOI: 10.1161/STROKEAHA.116.015204. View